Xeris Biopharma Holdings (XERS) Debt Ratio (2023 - 2026)

Xeris Biopharma Holdings has reported Debt Ratio for 4 years, with the latest figure at 0.56 in Q1 2026.

• For the quarter ending Q1 2026, Debt Ratio fell 22.52% year-over-year to 0.56; the trailing twelve-month figure through Mar 2026 stood at 0.56 (down 22.52% YoY), and the FY2025 full-year result was 0.57, down 20.04% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.56, down from 0.57 in the prior quarter.
• The five-year high for Debt Ratio was 0.73 in Q1 2025, with the low at 0.0 in Q2 2024.
• Historically, Debt Ratio has averaged 0.38 across 4 years, with a median of 0.57 in 2025.
• Annual changes were most pronounced in 2024 — Debt Ratio tumbled 97.5% — and 2025, when it surged 51494.53%.
• Xeris Biopharma Holdings' Debt Ratio stood at 0.59 in 2023, then increased by 21.39% to 0.72 in 2024, then slipped by 20.04% to 0.57 in 2025, then declined by 1.77% to 0.56 in 2026.
• The last three Debt Ratio figures came in at 0.56 (Q1 2026), 0.57 (Q4 2025), and 0.59 (Q3 2025), per Business Quant data.